Selank
NootropicsApproved (Russia, as anxiolytic and nootropic medication)Also known as: TP-7, Selank Spray
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro, 750 Da molecular weight) developed in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences as a synthetic analog of tuftsin — an immunomodulatory tetrapeptide (Thr-Lys-Pro-Arg) that is naturally cleaved from the Fc region of immunoglobulin G. The original tuftsin molecule has well-documented immunomodulatory and neurotropic effects but is rapidly degraded by peptidases in plasma, limiting its therapeutic utility.
Reconstitution Calculator for Selank
Pre-filled · 5mg vial · 250mcg dose
Overview
At A Glance
Primary Mechanism: Multi-System Neurochemical Modulation…
Mechanism of Action
Primary Mechanism: Multi-System Neurochemical Modulation
Selank does not have a single clean receptor-binding mechanism. Unlike benzodiazepines (GABA-A positive allosteric modulators), SSRIs (serotonin reuptake inhibition), or buspirone (5-HT1A partial agonism), Selank produces its anxiolytic and nootropic effects through coordinated modulation of multiple neurotransmitter systems. The most consistently documented mechanisms include:
GABAergic Modulation
Selank increases GABAergic tone in several brain regions, particularly the hypothalamus and limbic structures. Unlike benzodiazepines, this increase does NOT appear to be through direct GABA-A receptor binding. Instead, Selank appears to:
- Increase GABA release from presynaptic terminals
- Modulate GABA-A receptor subunit expression over time
- Enhance GABAergic signaling indirectly through kinase cascades
This GABAergic enhancement contributes to the anxiolytic effect but does so without producing the sedation, muscle relaxation, and cognitive dulling that benzodiazepines cause (Kozlovskaya et al., 2003).
Serotonergic Effects
Selank modulates serotonin metabolism, increasing brain serotonin turnover and affecting tryptophan uptake. Effects on specific 5-HT receptors are less well-characterized, but the compound appears to interact indirectly with serotonergic systems in a way that contributes to mood stabilization without the acute side effect burden of SSRIs (Samotrueva et al., 2011).
Endogenous Opioid System
Selank potentiates activity of endogenous opioid systems, particularly enkephalin-dependent pathways. This is thought to contribute to the mood-elevating effect and may explain the subjective sense of well-being that many users report. Unlike exogenous opioids, this potentiation does NOT produce dependence, tolerance, or respiratory depression. The effect appears to be modulation of enkephalinase enzymes (reducing enkephalin breakdown) rather than direct opioid receptor agonism.
BDNF and Neurotrophic Effects
Selank increases expression of brain-derived neurotrophic factor (BDNF), a key neurotrophin involved in synaptic plasticity, learning, memory, and adult neurogenesis. Elevated BDNF is a common downstream mechanism of antidepressants, exercise, and other pro-cognitive interventions. Selank's nootropic effects — improved concentration, memory, and cognitive endurance — are thought to partially derive from BDNF elevation over chronic dosing (Inozemtseva et al., 2008).
Immunomodulatory Effects
Selank inherits some immunomodulatory activity from its tuftsin parent. It affects cytokine expression, lymphocyte activation, and inflammatory markers in ways that may contribute to mood and cognitive effects through gut-brain axis and neuroinflammation pathways. This is less clinically relevant than the direct neuropharmacological effects but may contribute to long-term benefit.
Gene Expression and Epigenetic Effects
Emerging research suggests Selank modulates expression of genes involved in anxiety, depression, and memory circuits. The full scope of these effects is not well-characterized, but it contributes to the "long-tail" of clinical benefit that appears to outlast immediate plasma exposure.
Absence of Classical Receptor Binding
Extensive screening has not identified a single high-affinity receptor for Selank. Unlike most pharmacologically active peptides (oxytocin, vasopressin, opioids, angiotensin, etc.), Selank does not bind with high affinity to any known peptide receptor. This is unusual and has led researchers to propose that Selank:
- Activates multiple lower-affinity sites in parallel
- Modulates enzymatic activity (peptidases, kinases) rather than directly signaling through receptors
- Affects membrane properties or intracellular signaling in non-classical ways
- Binds to a receptor that remains uncharacterized
Whatever the molecular explanation, the clinical pharmacology is the empirical fact: intranasal Selank 300 mcg produces measurable anxiolytic and nootropic effects in humans that show up on psychiatric rating scales and in EEG measurements.
Pharmacokinetics
Selank is administered intranasally as a 0.15% aqueous solution (1.5 mg/mL). Each 0.05 mL (50 mcL) spray delivers 75 mcg of Selank; a typical 2-spray dose (one spray per nostril) delivers approximately 150 mcg, and 4 sprays deliver 300 mcg.
Key pharmacokinetic features:
- Rapid onset: Effects begin within 15-30 minutes of intranasal administration
- Peak effect: 30-60 minutes after dosing
- Duration of effect: 4-8 hours per dose, though some effects outlast plasma exposure
- Plasma half-life: Short — the intact peptide is cleared from blood within 1-2 hours
- Bioavailability: Substantially higher via intranasal than oral route due to bypass of GI peptidases
- CNS penetration: Intranasal delivery provides direct access via olfactory and trigeminal nerve pathways, bypassing the blood-brain barrier
- Metabolism: Enzymatic cleavage to smaller peptide fragments; some fragments may retain activity
- Accumulation: Does not accumulate with chronic dosing
Intranasal vs. Other Routes
Intranasal (standard): Optimal for CNS-targeted effects. Direct nose-to-brain delivery via olfactory pathway is the primary reason intranasal works well for neuropeptides.
Subcutaneous injection: Used in some research protocols and by some biohackers. May produce somewhat different profile emphasizing peripheral effects (immunomodulation, HPA axis). Not commonly used for anxiolytic indication.
Intramuscular injection: Used in research; not practical for home use.
Oral: Essentially ineffective due to GI peptidase degradation of peptide.
Sublingual: Limited data; may provide partial absorption but less characterized than intranasal.
Chronic Dosing Effects
Chronic Selank administration (weeks to months) appears to produce progressive benefits beyond acute effects:
- BDNF elevation that accumulates over weeks
- Gene expression changes affecting anxiety-related pathways
- Potential "trait" anxiolysis with diminishing acute effect over time but maintained baseline benefit
- No evidence of tachyphylaxis at therapeutic doses
This chronic effect pattern means Selank's full clinical value may only emerge over 4-8+ weeks of regular use, similar to SSRIs but without the initial activation/sedation side effects.
Overview
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro, 750 Da molecular weight) developed in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences as a synthetic analog of tuftsin — an immunomodulatory tetrapeptide (Thr-Lys-Pro-Arg) that is naturally cleaved from the Fc region of immunoglobulin G. The original tuftsin molecule has well-documented immunomodulatory and neurotropic effects but is rapidly degraded by peptidases in plasma, limiting its therapeutic utility. Selank adds a Pro-Gly-Pro tail to the tuftsin sequence, which confers resistance to enzymatic degradation while preserving pharmacological activity.
In Russia, Selank has been approved since 2004 for the treatment of generalized anxiety disorder (GAD) and is available by prescription at pharmacies across the Russian Federation and several neighboring countries. It is marketed as a 0.15% intranasal solution under the brand name "Selank" (╨í╨╡╨╗╨░╨╜╨║) by Peptogen, a Moscow-based pharmaceutical company. In Western markets, Selank has never been submitted for FDA, EMA, or other major regulatory approval — not because of unfavorable data, but because the commercial pharmaceutical industry has no mechanism to profit from a peptide with an expired patent and no Western development sponsor. As a result, Selank circulates in the biohacking and peptide-curious community primarily as a "research chemical" through specialty peptide suppliers, where it is sold in intranasal spray or injectable formulations.
The pharmacological profile of Selank is distinctive among anxiolytics. Unlike benzodiazepines, it does NOT cause sedation, cognitive dulling, tolerance, dependence, or withdrawal. Unlike SSRIs, it has rapid onset (within 30-60 minutes of intranasal administration) and effects that outlast plasma presence. Unlike buspirone, it does not require weeks of chronic dosing to manifest effects. The compound appears to work through modulation of multiple neurotransmitter systems simultaneously — GABAergic, serotonergic, dopaminergic, and endogenous opioid — producing what the Russian clinical literature describes as an "anxiolytic + nootropic" profile: the user feels calmer but also more mentally engaged, not sedated. This unusual combination has driven substantial interest in Western biohacking circles as an alternative or adjunct to conventional anxiety pharmacology.
Selank has been studied in Russian clinical populations for over two decades with a consistent efficacy and safety pattern across roughly 30-50 published clinical papers. The evidence base is real but has important limitations: most trials are Russian-language, published in Russian journals, with small sample sizes (often 30-100 patients), and use Russian psychiatric rating scales rather than the validated Western instruments (GAD-7, HAM-A, Beck Anxiety Inventory) that would facilitate cross-validation. Western meta-analyses and systematic reviews are essentially nonexistent. The Russian regulatory approval is real and meaningful — Russian drug regulation, while different from FDA standards, does require efficacy and safety evidence — but it does not automatically translate to confidence in Western evidence-based medicine frameworks.
For the biohacking community, Selank's appeal is the combination of (1) rapid-acting anxiolysis without sedation, (2) cognitive enhancement rather than dulling, (3) favorable safety profile across decades of Russian use, (4) non-addictive, non-dependence-producing pharmacology, and (5) intranasal delivery that is simple and needle-free. Its limitations are (1) thin Western evidence base, (2) variable quality from research chemical suppliers, (3) lack of FDA regulation or oversight, (4) modest effect magnitude in some users relative to expectations, and (5) cost relative to generic anxiety pharmacology. This entry covers the pharmacology, clinical evidence, practical use considerations, and honest framing of the evidence gaps. Cross-reference with Semax, DSIP, and Epithalon for a complete picture of the Russian research peptide landscape.
Chemical Information
IUPAC Name
Thr-Lys-Pro-Arg-Pro-Gly-Pro
CAS Number
129843-05-03
Molecular Formula
C33H57N11O9
Molecular Mass
751.87 g/mol
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Interaction Matrix
Contraindications
Absolute Contraindications
Selank should NOT be used in the following circumstances:
- Known allergy or hypersensitivity to Selank or components
- Pregnancy: Insufficient safety data; peptide effects on developing nervous system not characterized
- Lactation: Insufficient safety data
- Active psychosis or severe psychiatric emergencies: Requires specialist management with established medications
- Severe untreated medical conditions potentially manifesting as anxiety: Thyrotoxicosis, pheochromocytoma, arrhythmia — treat the underlying condition
Relative Contraindications / Caution Warranted
- Pediatric use: Limited data; some Russian clinical use in children but Western practice would be to avoid
- Moderate to severe liver disease: Peptide clearance generally preserved but data in severe hepatic impairment is limited
- Moderate to severe kidney disease: Same consideration
- Active substance use disorder: Selank itself not addictive, but complete treatment approach needed
- Severe anxiety requiring urgent care: Selank is adjunctive; severe panic or suicidal anxiety need professional evaluation
- Nasal pathology: Chronic rhinitis, deviated septum, nasal polyps may impair absorption; consider injection route or treat nasal condition
Psychiatric Considerations
- Active suicidal ideation: Professional psychiatric care is primary; Selank is not sufficient alone
- Severe depression: Selank has modest mood effect; not a substitute for antidepressants in major depression
- PTSD: Selank may be useful adjunct but complete trauma-focused care (therapy, sometimes medication) is primary
- Bipolar disorder: Manic or hypomanic episodes require specific management; Selank has no established role in mood stabilization
- Panic disorder: May help but often insufficient; complete CBT ± SSRI is first-line
- OCD: Modest effect possible but high-dose SSRI is first-line
Drug Interactions
Formal interaction studies are limited. Based on pharmacology:
- SSRIs/SNRIs: No known dangerous interaction; combination sometimes useful; theoretical serotonin syndrome concern with very high doses of either
- MAOIs: Theoretical concern due to serotonergic component; prudent to avoid
- Tricyclic antidepressants: No significant interaction expected
- Benzodiazepines: Combined often useful, no dangerous interaction; additive anxiolysis (desired)
- Buspirone: Compatible combination
- Opioids: Theoretical interaction via opioid system modulation; clinically non-problematic in limited reports
- Alcohol: No dangerous interaction; but alcohol disrupts anxiety management
- Stimulants: No dangerous interaction; may counter stimulant anxiety
- Antipsychotics: No specific interactions noted
- Lithium: No known interaction
- Anticonvulsants: No known interaction
- Other research peptides (Semax, DSIP, etc.): Commonly stacked without reported issues
Medical Conditions Requiring Caution
- Cardiovascular disease: No specific CV effects noted, but any new medication in unstable CV disease requires consideration
- Endocrine disorders: Thyroid dysfunction should be treated — anxiety may have endocrine cause
- Chronic respiratory disease: Peptide itself is respiration-neutral; nasal delivery may irritate in severe rhinitis/sinusitis
- Migraine disorders: No specific interaction; nasal spray may worsen migraine in some sensitive users
- Seizure disorders: No known effect on seizure threshold; baseline caution with any neuroactive compound
- Immunocompromised states: Selank's immunomodulatory effects are mild but discuss with treating physician
Contraindicated Combinations
While Selank is generally safe in combination, these combinations warrant specific caution:
- MAOIs + Selank: Theoretical serotonin syndrome risk; avoid
- Multiple serotonergic agents at high doses: SSRI + SNRI + Selank + 5-HTP + St. John's wort — serotonin toxicity risk
- Multiple sedatives: Selank + benzodiazepine + alcohol + opioid — additive CNS effects
- Complex polypharmacy without physician oversight: Unpredictable interactions
Physical Examination and Workup Before Starting
For anxiety that has not been medically evaluated:
- TSH and free T4: Hyperthyroidism presents as anxiety
- Caffeine intake assessment: Common overlooked cause
- Substance use history: Cannabis, stimulants, alcohol — treat underlying issue
- Sleep evaluation: Poor sleep causes anxiety
- Cardiac evaluation if palpitations/chest symptoms: EKG, consider Holter
- B12, folate, vitamin D: Deficiencies can manifest as mood/anxiety symptoms
- Blood glucose, HbA1c: Dysglycemia affects mood
- Testosterone if male: Low T associated with anxiety in some men
- Menopausal status if female: Perimenopausal anxiety common
- Medication review: Current medications that could contribute to anxiety
Safety Monitoring
Selank itself doesn't require specific lab monitoring. General wellness monitoring is reasonable as part of broader health maintenance.
Symptoms warranting discontinuation or medical evaluation:
- Severe or unusual headache
- Any allergic-type reaction
- Unexpected mood changes (severe depression, mania, psychosis)
- Worsening rather than improving anxiety
- Physical symptoms suggesting systemic reaction
Pregnancy and Fertility
No data in pregnancy or lactation. Avoid.
Effects on fertility: Not documented in either direction.
For couples trying to conceive: prudent to avoid the female partner's use; male use less concerning but data absent.
Pediatric Use
Some Russian clinical use in children with anxiety exists, but:
- Western practice would typically avoid in minors
- Non-pharmacological interventions (therapy, environmental modification, behavioral support) should be primary
- If medication indicated, established pediatric psychiatric care with approved agents is preferred
Elderly Considerations
Standard doses typically appropriate:
- Start at 150 mcg to assess tolerability
- Monitor for mild fatigue (uncommon but possible)
- No specific dose reduction required
- Favorable cognitive profile compared to benzodiazepines (which are discouraged in elderly)
- Useful option in elderly where BZDs are problematic
Driving and Machinery
Selank does NOT impair driving, coordination, or reaction time at therapeutic doses in the vast majority of users. Assess individual response before safety-critical activities. Most users experience no impairment at any dose.
Occupational Considerations
- Not on current WADA prohibited list (verify before competition)
- Not routinely tested in workplace drug screening
- Not scheduled/controlled in most jurisdictions (exception: Russia treats as prescription)
- Safety-critical professions (pilots, surgeons, operators): verify individual tolerance
Long-Term Use Philosophy
While Selank appears safe for long-term use based on Russian clinical experience (15+ years of approval), the spirit of good pharmacology is to:
- Use the minimum dose that achieves the goal
- Periodic breaks rather than continuous use
- Combine with non-pharmacological approaches (therapy, lifestyle)
- Regularly reassess ongoing need
- Avoid drift toward polypharmacy without clear rationale
Indefinite nightly use of any anxiolytic, even a safe one, reflects either (1) untreated underlying condition, (2) lifestyle factors not addressed, or (3) psychological dependence that may benefit from reassessment. The goal is flexibility and function, not permanent pharmacology.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$25.00
up to $50.00
$3.4650
6
7
vial, spray
Tracking since Mar 13, 2026 · 6 data points
Price History
5 data pointsVendors Selling Selank
Ion Peptide
ResearchChemHQ
Optimum Formula
VANDL Labs
Nova Peptides
Adera
How we score these vendors
Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.
Related Compounds
View All9-MBC (9-Methyl-β-carboline)
NootropicsPreclinical9-Methyl-β-carboline (9-MBC) is a synthetic β-carboline alkaloid that has gained significant interest in the nootropic community for its reported ability to promote dopaminergic neuron growth, increase dopamine synthesis enzymes, and provide neuroprotective effects against neurotoxins.
Bromantane
NootropicsRussia ApprovedBromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten.
Dihexa
NootropicsPreclinicalDihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University.
Kavain
NootropicsPreclinicalActive compound from kava for relaxation and sleep support..
L-Theanine
NootropicsFDA ApprovedL-Theanine is a non-proteinogenic amino acid found almost exclusively in tea (Camellia sinensis) and a handful of edible mushrooms, and it has become the single most widely-used calm-focus nootropic in the modern supplement market — both on its own at 100-400mg doses and, even more prominently, as the classic 1:1 or 2:1 pair with caffeine that defines the "calm-focus" experiential signature of green tea and of virtually every serious nootropic stack.
L-Tyrosine
NootropicsPreclinicalL-Tyrosine is a non-essential aromatic amino acid and the direct biosynthetic precursor to the catecholamine neurotransmitters dopamine, norepinephrine, and epinephrine.
Side-by-Side Comparisons
All ComparisonsView Full Dosage Guide →
Protocols, calculator & safety for Selank
Related Articles
All PostsThe Best Peptide Nasal Sprays of 2026, Ranked by Evidence
Evidence-tiered review of 10 peptide nasal sprays — Semax, Selank, Oxytocin (S); PT-141, DSIP, Epithalon (A); Noopept, NAD+, 5-Amino-1MQ (B); Melanotan-II (C). Human-trial counts, PMID citations, safety, dosing, and pre-made vs DIY tradeoffs. Tiers match the live pillar scorecard.
4/21/2026How to Make a Peptide Nasal Spray at Home — The Complete DIY Guide (2026)
Full DIY protocol for reconstituting peptides into nasal sprays — Semax, Selank, oxytocin, DSIP, BPC-157. Reconstitution math, sterile technique, storage, pH/tonicity, safety. 11-step protocol with worked examples.
4/21/2026The Complete Peptide Reconstitution Guide — Every Peptide, Every Ratio, Every Pitfall (2026)
The master reconstitution reference for 17 peptides. BAC vs SWFI vs acetic acid, mg/mL targets, IU math on U100 syringes, storage and stability by peptide class, sterile technique, and the mistakes that destroy $60 vials. Includes worked examples for BPC-157, TB-500, GHK-Cu, semaglutide, tirzepatide, CJC-1295, ipamorelin, sermorelin, GHRPs, Melanotan II, PT-141, oxytocin, Semax, Selank, DSIP, and epithalon.
4/21/2026Research Score
88 PubMed studies
Quality Indicators
Data Completeness
100%COA Verification
10
Verified COAs
2
Vendors w/ COA
High verification rate (83%)
Latest test: 3/1/2026
Research Credibility
Well-researched compound
Quick Facts
Half-Life
~2-3 minutes plasma half-life (functional anxiolytic and nootropic effects persist 12-24 hours due to gene expression and neurotransmitter modulation)
Molecular Weight
751.87 g/mol
Administration
Intranasal
CAS Number
129843-05-03
Trial Phase
Approved (Russia, as anxiolytic and nootropic medication)
Safety Profile
Common Side Effects
- • Mild nasal irritation or tingling with intranasal administration
- • Transient mild fatigue during first few days of use
- • Slight metallic taste reported by some users
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is Selank and where is it from?
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It's a stabilized synthetic analog of tuftsin, a naturally-occurring immunomodulatory peptide. Selank has been approved as a prescription anxiolytic in Russia since 2004 under the brand name Selank (Селанк), manufactured by Peptogen. In Western markets, it is sold as a 'research chemical' through peptide suppliers because no Western pharmaceutical company has pursued FDA approval.
Is Selank approved by the FDA?
No. Selank is approved by the Russian Federation state drug regulatory agency (Roszdravnadzor) for generalized anxiety disorder, but has never been submitted for FDA approval. This is primarily a commercial decision — the molecule is off-patent and no Western company has sufficient financial incentive to pursue development. The evidence base exists in Russian clinical literature but not in the large Western-standard trials that FDA requires. Selank circulates in the US exclusively through research peptide suppliers.
How does Selank compare to benzodiazepines?
Selank produces anxiolytic effects comparable to benzodiazepines in Russian comparative trials (Zozulya et al., 2008) but with a dramatically different profile: NO sedation, NO cognitive impairment, NO dependence, NO tolerance, NO withdrawal. Selank users maintain or improve cognitive performance while anxious symptoms reduce. Benzodiazepines cause sedation, memory problems, and create dependence within weeks to months. For mild-to-moderate chronic anxiety, Selank's profile is clearly favorable; for severe acute anxiety or panic, benzodiazepines' rapid and strong effect may still be preferred.
How should I dose Selank for anxiety?
Standard starting dose is 150 mcg (1 spray each nostril) morning for first week, then increase to 300 mcg (2 sprays each nostril) morning. For ongoing anxiety, consider adding afternoon dose of 150-300 mcg. Total daily dose typically 300-600 mcg; Russian therapeutic protocols use up to 900 mcg daily divided into 2-3 doses. For acute situational anxiety (public speaking, medical appointments), 150-300 mcg 30-60 minutes before the event. Take 2-4 week courses with 1-2 week breaks.
How quickly does Selank work?
Acute anxiolytic effects begin within 15-30 minutes of intranasal administration, peak at 30-60 minutes, and last 4-8 hours per dose. Chronic effects (BDNF elevation, gene expression changes) accumulate over weeks of regular use, producing sustained 'trait' improvements in anxiety baseline over 2-8 weeks. This fast-onset + chronic-accumulation profile distinguishes Selank from SSRIs (slow onset, purely chronic) and benzodiazepines (fast onset, purely acute).
Can Selank be used with antidepressants?
Yes, commonly and safely. Selank has no known dangerous interaction with SSRIs (sertraline, escitalopram, fluoxetine, etc.) or SNRIs (venlafaxine, duloxetine). It can be particularly useful as a rapid-acting adjunct during the 2-4 week SSRI onset period or for residual anxiety on stable SSRI therapy. Theoretical serotonin syndrome concern exists only at very high combined doses; at standard dosing this is not a clinical issue. Consult your prescribing clinician, especially if taking multiple psychiatric medications.
What are Selank's side effects?
Selank has one of the best safety profiles in the anxiolytic space. Common: mild nasal irritation (10-15%), mild headache (5-10%), altered taste during administration. Uncommon: dizziness, mild fatigue, nausea. NOT reported: dependence, tolerance, withdrawal, cognitive impairment, sexual dysfunction, weight gain, emotional blunting. Over 15+ years of Russian clinical use, no serious adverse events have been reported. This favorable profile is one of the main reasons for Selank's popularity in biohacking communities.
Is Selank addictive?
No. Selank has NO addiction liability. Russian pharmacovigilance over 15+ years of clinical use has not identified dependence, tolerance, withdrawal syndromes, or abuse patterns. This fundamentally distinguishes Selank from benzodiazepines, opioids, alcohol, and other anxiolytics that produce dependence. Selank can be stopped abruptly without medical supervision and restarted as needed without dose escalation. This profile makes it particularly suitable for users concerned about dependence with conventional anxiolytics.
Does Selank work for cognitive enhancement?
Yes, modestly. Selank produces cognitive improvements beyond what anxiolysis alone explains (Medvedev et al., 2014), including attention, psychomotor speed, and working memory. The mechanism appears to involve BDNF elevation, gene expression effects, and multi-neurotransmitter modulation. However, cognitive effects are modest — not dramatic. Selank is better characterized as 'cognition-preserving + mild enhancement' than a strong nootropic. For stronger cognitive effects, it's often stacked with Semax which has more direct nootropic activity.
What's the difference between Selank and Semax?
Both are Russian intranasal peptides with overlapping but distinct profiles. Semax is primarily a nootropic (cognition, focus, alertness) derived from ACTH, acting strongly on BDNF, dopamine, and neurotrophic systems. Selank is primarily anxiolytic (calm, stress tolerance) derived from tuftsin, acting on GABA, serotonin, and opioid systems. Semax makes you more alert and focused; Selank makes you calmer without sedation. Combined, they produce 'calm focus' and are frequently stacked: Semax morning for cognitive activation, Selank PRN or standing for anxiety management. Both have similar safety profiles and Russian regulatory approval.
Research Tools
Related Compounds
View All9-MBC (9-Methyl-β-carboline)
NootropicsPreclinical9-Methyl-β-carboline (9-MBC) is a synthetic β-carboline alkaloid that has gained significant interest in the nootropic community for its reported ability to promote dopaminergic neuron growth, increase dopamine synthesis enzymes, and provide neuroprotective effects against neurotoxins.
Bromantane
NootropicsRussia ApprovedBromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten.
Dihexa
NootropicsPreclinicalDihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University.
Kavain
NootropicsPreclinicalActive compound from kava for relaxation and sleep support..
L-Theanine
NootropicsFDA ApprovedL-Theanine is a non-proteinogenic amino acid found almost exclusively in tea (Camellia sinensis) and a handful of edible mushrooms, and it has become the single most widely-used calm-focus nootropic in the modern supplement market — both on its own at 100-400mg doses and, even more prominently, as the classic 1:1 or 2:1 pair with caffeine that defines the "calm-focus" experiential signature of green tea and of virtually every serious nootropic stack.
L-Tyrosine
NootropicsPreclinicalL-Tyrosine is a non-essential aromatic amino acid and the direct biosynthetic precursor to the catecholamine neurotransmitters dopamine, norepinephrine, and epinephrine.
Side-by-Side Comparisons
All ComparisonsCompare Selank head-to-head: mechanism, half-life, dosing, safety, and live pricing.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.